演題抄録

臓器別シンポジウム

開催概要
開催回
第58回・2020年・京都
 

HER2過剰発現を認める進行・再発乳癌に対する最新治療

演題番号 : SY20-3

[筆頭演者]
石田 孝宣:1 

1:東北大学・乳腺・内分泌外科

 

The treatment strategy for HER2-positive advanced and metastatic breast cancer has made great progress, and the prognosis after metastasis is almost the same as that of the Luminal subtype breast cancer. With the advent of Pertuzumab, Trastuzumab + Pertuzumab + Docetaxel has been strongly recommended as the first-line treatment for advanced and metastatic disease. In addition, Trastuzumab emtansine has established its position as a first or second-line treatment, and from this year, trastuzumab deruxtecan has emerged as a new drug for the patients who had received previous treatment with trastuzumab emtansine. Trastuzumab deruxtecan shows durable antitumor activity with a confirmed overall response rate of 60.9%, a median duration of progression-free survival of 16.4 months, greatly expanding the range of treatment options. Furthermore, the effectiveness of Tucatinib has been reported. In heavily pretreated patients with HER2-positive metastatic breast cancer, including those with brain metastases, Tucatinib + Trastuzumab + Capecitabine resulted in excellent progression-free survival and overall survival outcomes. On the other hand, since each drug has its own characteristic adverse events such as interstitial lung disease and palmar-plantar erythrodysesthesia syndrome, proper management is required. In this session, I will summarize and report this information, and also introduce the creation of new technology and clinical application in collaboration with medical engineering and medical physics for the quantification of HER2 protein using Trastuzumab-conjugated quantum dots and phosphor-integrated dots developed at Tohoku University.

前へ戻る